| Owner | Public |
|---|---|
| URN | urn:agi-Regulation:inout-urn:agi-llid:552:out-urn:agi-gocellproc:0042310::unknown |
| References | 12 |
| Connectivity | 2 |
| Effect | unknown |
| MedLine Reference | 10564825:0 |
|---|---|
| Sentence | Arginine vasopressin interacts with the vasopressin type 1a receptor (V1aR) to initiate physiological effects such as vasoconstriction of blood vessels and glycogenolysis. |
| MedLine Reference | 12724283:0 |
|---|---|
| Sentence | The arginine vasopressin (AVP) type 1a receptor (V1a) is well known to mediate vasoconstriction. |
| Journal Link | http://ajpregu.physiology.org/cgi/content/full/282/4/R979 |
|---|---|
| CellLineName | VSMCs |
| CellType | hepatocyte |
| MedLine Reference | 11893600:10154 |
| Sentence | Together, our data suggest that proinflammatory cytokines downregulate V1A receptor expression during sepsis, causing an attenuation of the V1A receptor-mediated vasoconstriction. |
| Journal | Reg.Int.Comp.Phys |
| Journal Reference | v282 i4 pR979 |
| Journal Link | http://www.ebmonline.org/cgi/content/full/229/10/1061 |
|---|---|
| Organ | brain |
| MedLine Reference | 15522843:10230 |
| Sentence | V1a, unlike V2a, is recognized to initiate vasoconstriction upon binding of its ligand vasopressin (anti-diuretic hormone, ADH). |
| Journal | EBM |
| Journal Reference | v229 i10 p1061 |
| Organ | kidney |
|---|---|
| MedLine Reference | 11330329:3 |
| Sentence | Oxytocin-evoked renal vasoconstriction was abolished by SR 49059, a selective vasopressin V1A receptor antagonist (10 nM), but not by d(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr-(NH2)9] vasotocin, an oxytocin receptor antagonist (10 nM). |
| Journal Link | http://ajprenal.physiology.org/cgi/content/full/290/2/F273 |
|---|---|
| Organ | kidney |
| MedLine Reference | 16189291:10182 |
| Sentence | A theoretical problem could arise because the circulating AVP, which can no longer bind to the V 2 receptor, is available to bind to the V 1A receptor, which mediates vasoconstriction. |
| Journal | Renal Phys |
| Journal Reference | v290 i2 p273 |
| Journal Link | http://ajpendo.physiology.org/cgi/content/full/285/6/E1161 |
|---|---|
| Tissue | smooth muscle |
| MedLine Reference | 12915399:10122 |
| Sentence | Another major action of AVP is vasoconstriction, which is mediated by V1aR in vascular smooth muscle cells. |
| Journal | Endocrin. Metabol |
| Journal Reference | v285 i6 pE1161 |
| Journal Link | http://jpet.aspetjournals.org/cgi/content/full/293/3/852 |
|---|---|
| Tissue | smooth muscle |
| MedLine Reference | 10869385:10029 |
| Sentence | Activation of the V 1a receptor has been shown to cause peripheral vasoconstriction (Riegger and Leibau, 1982 ; Manning et al., 1993 ; Bichet, 1994 , Burrell et al., 1994 ). |
| Journal | JPET |
| Journal Reference | v293 i3 p852 |
| Tissue | vascular |
|---|---|
| Organ | renal |
| MedLine Reference | 10731046:8 |
| Sentence | In the presence of SR 49059 (1 mg/kg i.v.), a vasopressin V1A receptor antagonist that completely abolished the vasopressin-induced renal vasoconstriction, desmopressin again failed to induce vasodilation. |
| Journal Link | http://www.pnas.org/cgi/content/full/103/20/7807 |
|---|---|
| Tissue | endothelial |
| MedLine Reference | 16682631:10137 |
| Sentence | Therefore, the magnitude of the BP increase seen after in vivo administration of AVP actually represents a summation of V1a receptor-mediated vasoconstriction and V2 receptor/NO-mediated vasodilatation. |
| Journal | PNAS |
| Journal Reference | v103 i20 p7807 |
| Journal Link | http://ajprenal.physiology.org/cgi/content/full/291/1/F218 |
|---|---|
| Tissue | medulla |
| MedLine Reference | 16478974:10025 |
| Journal | Renal Phys |
| Journal Reference | v291 i1 p218 |
| Journal Link | http://ajprenal.physiology.org/cgi/content/full/288/6/F1249 |
|---|---|
| Tissue | vascular |
| MedLine Reference | 15657301:10028 |
| Journal | Renal Phys |
| Journal Reference | v288 i6 p1249 |